公开(公告)号：US5116871A

公开(公告)日：1992-05-26

申请号：US397789

申请日：1989-08-24

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K38/21 ,  A61P9/00 ,  A61P25/00 ,  A61P25/04 ,  A61P29/00 ,  A61P31/12 ,  A61P43/00

CPC classification number: A61K31/20 ,  A61K38/21

Abstract: The use of one or more of the 6-desaturated or higher EFAs of each of the n-6 and n-3 series for the manufacture of a medicament for use in the treatment of post-viral fatigue syndrome (otherwise known as myalgic encephalomyelitis (ME)).

公开(公告)号：US5116624A

公开(公告)日：1992-05-26

申请号：US638998

申请日：1991-01-09

Applicant: David F. Horrobin ,  Frank Corrigan

Inventor： David F. Horrobin ,  Frank Corrigan

IPC: A61K31/20 ,  A61K31/202 ,  A61K31/315 ,  A61K33/04 ,  A61K33/30 ,  A61K35/60 ,  A61K36/00 ,  A61K36/18 ,  A61P25/24 ,  A61P25/26 ,  A61P25/28

CPC classification number: A61K33/04 ,  A61K31/315 ,  A61K33/30 ,  A61K35/60 ,  A61K36/06

Abstract: A pharmaceutical composition of GLA or DGLA and bioavailable selenium, optionally also with an 18:4 or higher n-3 EFA and/or bioavailable zinc.

公开(公告)号：US4886670A

公开(公告)日：1989-12-12

申请号：US159128

申请日：1988-02-23

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

CPC classification number: A61K31/70 ,  A61K31/19 ,  A61K31/505 ,  A61K33/14 ,  A61K38/21

Abstract: The anti-viral effectiveness of conventional anti-viral agents such as acylovir, idoxuridine, vidarabine etc. is enhanced by formulation or administration with a physiologically acceptable lithium salt.

Abstract translation: 常规抗病毒剂如acylovir，idoxuridine，阿糖腺苷等的抗病毒效能通过与生理上可接受的锂盐的配制或施用来增强。

公开(公告)号：USRE31836E

公开(公告)日：1985-02-19

申请号：US581671

申请日：1984-02-16

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K33/30 ,  A61K45/06

CPC classification number: A61K33/30 ,  A61K31/20 ,  A61K31/23 ,  A61K31/375 ,  A61K31/43 ,  A61K31/485 ,  A61K45/06

Abstract: Composition and use of .gamma.-linolenic acid and related materails with ascorbic acid, or ethyl alcohol, or an opiate antagonist such as naloxone, nalorphine or levallorphan, for treating alcoholism or moderating the effects of taking alcohol.

公开(公告)号：US4444755A

公开(公告)日：1984-04-24

申请号：US272081

申请日：1981-06-10

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/43 ,  A61K31/545 ,  A61K33/30 ,  A61K31/20 ,  A61K31/315 ,  A61K31/54

CPC classification number: A61K33/30 ,  A61K31/43 ,  A61K31/545

Abstract: Use of .gamma.-linolenic acid and related materials alone or with zinc or .beta.-lactam antibiotics to treat skin disorders.

Abstract translation: 单独或与锌或β-内酰胺抗生素一起使用γ-亚麻酸及相关物质治疗皮肤病。

公开(公告)号：US4309415A

公开(公告)日：1982-01-05

申请号：US29058

申请日：1979-04-11

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A23L1/29 ,  A23L1/30 ,  A61K31/20 ,  A61K31/202 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K38/00 ,  A61K38/21 ,  A61K45/06 ,  A61P13/02 ,  A61P15/00 ,  A61P29/00 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  A61K45/02 ,  A61K31/54

CPC classification number: A61K38/21 ,  A61K31/20 ,  A61K31/23 ,  A61K31/34 ,  A61K31/40 ,  A61K31/425 ,  A61K31/43 ,  A61K31/475 ,  A61K31/557 ,  A61K33/30 ,  A61K45/06

Abstract: Compositions and use of .gamma.-linolenic acid and related materials with (i) zinc, .beta.-lactam antibiotics or other materials enhancing physiological 1-series PG synthesis and/or (ii) colchicine, Vinca alkaloids or other materials enhancing physiological synthesis of thromboxane A2, for treatment of inflammatory disorders.

Abstract translation: γ-亚麻酸及相关材料与（i）锌，β-内酰胺抗生素或其他增强生理性1系PG合成的物质和/或（ii）秋水仙碱，长春花生物碱或其他增强凝血恶烷A2生理合成的物质的组合和用途 ，用于治疗炎症性疾病。

公开(公告)号：US4287202A

公开(公告)日：1981-09-01

申请号：US38938

申请日：1979-05-14

Applicant: David F. Horrobin

Inventor： David F. Horrobin

IPC: A61K31/405 ,  A61K31/47

CPC classification number: A61K31/405 ,  A61K31/47

Abstract: A method for the treatment or prophylaxis of angina pectoris or myocardial infarction which consists of administering indomethacin or chloroquine. It has been found that angina pectoris and myocardial infarction may be susceptible to treatment by administration of substances which will inhibit the synthesis or action of prostaglandins, which it is believed to be the effect of administering indomethacin or chloroquine.

Abstract translation: 治疗或预防心绞痛或心肌梗死的方法，其包括给予吲哚美辛或氯喹。 已经发现，心绞痛和心肌梗塞可能通过施用将抑制前列腺素合成或作用的物质来治疗，这被认为是施用吲哚美辛或氯喹的作用。

公开(公告)号：US5990164A

公开(公告)日：1999-11-23

申请号：US930701

申请日：1998-03-17

Applicant: David F. Horrobin ,  Philip Knowles ,  Mehar Manku ,  John C. Stewart

Inventor： David F. Horrobin ,  Philip Knowles ,  Mehar Manku ,  John C. Stewart

IPC: A23L1/30 ,  A61K8/00 ,  A61K8/30 ,  A61K8/33 ,  A61K8/36 ,  A61K8/41 ,  A61K31/20 ,  A61K31/202 ,  A61Q5/02 ,  C07C57/03 ,  C07C215/10 ,  A61K31/215

CPC classification number: C07C57/03 ,  C07C215/10

Abstract: An N-alkylpolyhydroxyamine salt of an n-6 or n-3 essential fatty acid (EFA) that is beyond the 6-desaturation step, or of any polyunsaturated fatty acid, other than those belonging to the n-6 and n-3 series, having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, the salt being formed with the fatty acid either as such or in the form of a covalent derivative, through the carboxyl group, of a bifunctional compound itself having a free acid function.

Abstract translation: PCT No.PCT / GB96 / 00952 Sec。 371日期：1998年3月17日 102（e）1998年3月17日PCT 1996年4月19日PCT PCT。 出版物WO96 / 33155 日期1996年10月24日除了6-去饱和步骤以外的n-6或n-3必需脂肪酸（EFA）的N-烷基多羟基胺盐或任何多不饱和脂肪酸，属于n-6 和n-3系，具有16至26个碳原子和多至六个双键，双键呈顺式或反式构型，盐与脂肪酸形成或者以共价衍生物形式， 通过羧基，具有游离酸功能的双官能化合物本身。

公开(公告)号：US5922345A

公开(公告)日：1999-07-13

申请号：US584426

申请日：1996-01-11

Applicant: David F. Horrobin ,  Lars Lindmark

Inventor： David F. Horrobin ,  Lars Lindmark

IPC: A23L1/29 ,  A23L1/30 ,  A61K31/202 ,  A61K31/23

CPC classification number: A61K31/202 ,  A23L33/12 ,  A23L33/40

Abstract: Countering side effects of parenteral or fluid-diet enteral nutrition by adding one or more 6-desaturated essential fatty acids (EFAs) to parenteral or enteral composition (particularly low-fat compositions) being given, or giving them in addition to the compositions.

Abstract translation: 通过向给予的肠胃外或肠内组合物（特别是低脂肪组合物）中加入一种或多种6-去饱和必需脂肪酸（EFAs）或给予它们以补充组合物来抵抗肠胃外或流体饮食肠内营养的副作用。

公开(公告)号：US5859055A

公开(公告)日：1999-01-12

申请号：US557545

申请日：1995-11-14

Applicant: David F. Horrobin ,  John C. M. Stewart

Inventor： David F. Horrobin ,  John C. M. Stewart

IPC: A61K31/20 ,  A61K31/202 ,  A61P9/00 ,  A61P9/10 ,  C07C57/03 ,  C07C57/12 ,  A61K31/22

CPC classification number: A61K31/20 ,  Y10S514/824

Abstract: Gamma-linolenic acid and/or dihomo-gamma-linolenic acid is used in the preparation of a medicament for inhibiting reocclusion of an artery from which an occlusion or other blockage has been removed, or for preventing occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.

Abstract translation: γ-亚麻酸和/或二 - γ-亚麻酸用于制备用于抑制已经从其中除去闭塞或其它阻塞的动脉再闭塞或用于防止外周或冠状动脉闭塞的药物中的用途。 药物还可以包含二十碳五烯酸。